Acceptability of a first-line anti-tuberculosis formulation for children: qualitative data from the SHINE trial. (2019)
Attributed to:
Paediatric and adolescent infections
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.5588/ijtld.19.0115
PubMed Identifier: 31931909
Publication URI: http://europepmc.org/abstract/MED/31931909
Type: Journal Article/Review
Volume: 23
Parent Publication: The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease
Issue: 12
ISSN: 1027-3719